Research programme: autoimmune therapeutics - LongBio Pharma
Latest Information Update: 25 Sep 2023
At a glance
- Originator LongBio Pharma
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 27 Jun 2023 Preclinical trials in Autoimmune disorders in China (Parenteral), prior to June 2023 (LongBio Pharma pipeline, June 2023)